Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia
T. Wilhelm, M. A. Toledo, I. Simons, C. Stuth, V. Mohta, R. Mülfarth, M. Nitsche, K. Maschke-Neuss, S. Schmitz, A. Kaiser, M. Arock, M. Zenke, M. Huber
The paper shows that combining low-dose Ponatinib and Trametinib can overcome Imatinib resistance in mast cell leukemia by inhibiting paradoxical MAPK pathway activation.
bioRxiv · Aug 31, 2020Cancer Biology